ITCI Intra-Cellular Therapies Inc.

9.81
-0.17  -2%
Previous Close 9.98
Open 10.19
Price To Book 2.39
Market Cap 542,110,675
Shares 55,261,027
Volume 836,104
Short Ratio
Av. Daily Volume 801,996
Stock charts supplied by TradingView

NewsSee all news

  1. Intra-Cellular Therapies to Present Data on Lumateperone and ITI-333 at the 58th Annual Meeting of the American College of Neuropsychopharmacology

    NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today

  2. Intra-Cellular Therapies to Present at the 2019 Cantor Global Healthcare Conference

    NEW YORK, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today

  3. Intra-Cellular Therapies Announces Progression to Higher Dose Cohort in ITI-214 Translational Medicine Study in Patients with Heart Failure

    Data indicate ITI-214 at a dose of 30 mg is well tolerated with a favorable safety profile Study ‘104 now proceeding to a third cohort at a dose of 90 mg NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular

  4. Intra-Cellular Therapies Provides Lumateperone Regulatory Update

    FDA has informed the Company it has no plans to schedule an Advisory Committee Meeting Company has completed submission of non-clinical information previously agreed with FDA  NEW YORK, Sept. 10, 2019 (GLOBE

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial did not meet primary endpoint - July 8, 2019.
ITI-007 - Monotherapy (Study 401)
Bipolar depression
Phase 3 interim analysis December 18, 2018 noted trial to stop due to futility.
ITI-007-201
Agitation in patients with dementia
PDUFA date extended by three months to December 27, 2019. No advisory committee meeting expected.
Lumateperone
Schizophrenia
Phase 3 top-line data due mid-2020.
ITI-007-402
Bipolar depression
Phase 3 trial met primary endpoint - July 8, 2019.
ITI-007 - Monotherapy (Study 404)
Bipolar depression
Phase 1/2 top-line presented October 22, 2018.
ITI-214
Parkinson's disease (PD)
Phase 1/2 top-line data due 1H 2020.
ITI-214-105
Heart failure

Latest News

  1. Intra-Cellular Therapies to Present Data on Lumateperone and ITI-333 at the 58th Annual Meeting of the American College of Neuropsychopharmacology

    NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today

  2. Intra-Cellular Therapies to Present at the 2019 Cantor Global Healthcare Conference

    NEW YORK, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today

  3. Intra-Cellular Therapies Announces Progression to Higher Dose Cohort in ITI-214 Translational Medicine Study in Patients with Heart Failure

    Data indicate ITI-214 at a dose of 30 mg is well tolerated with a favorable safety profile Study ‘104 now proceeding to a third cohort at a dose of 90 mg NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular

  4. Intra-Cellular Therapies Provides Lumateperone Regulatory Update

    FDA has informed the Company it has no plans to schedule an Advisory Committee Meeting Company has completed submission of non-clinical information previously agreed with FDA  NEW YORK, Sept. 10, 2019 (GLOBE